Peptide vendors that shut down or faced enforcement, 2024–2026: the record

Why this list exists

When a peptide vendor disappears, the people searching for it are its customers: did my order ship, is my stock safe, is the new site with the same name the same company. The answers are scattered across newsletters, forum threads and FDA pages that do not link to each other. PepAssure keeps them in one place — the Enforcement & Shutdown Watch — with a source for every entry and a dated "what happened" section on each vendor's page. This post is the same record, in date order, written out.

Two rules shape it. An enforcement entry needs a government document (FDA, DOJ or FTC). A reported shutdown needs a dated industry or reference record, and is labelled as a report. Entries flagged as exit scams are published on the watch page only, with their evidence status, and are not repeated here.

The record, oldest first

• •Tailor Made Compounding — DOJ (E.D. Kentucky). The company pleaded guilty to distributing unapproved new drugs including BPC-157, CJC-1295 and Ipamorelin between October 2018 and April 2020 and forfeited about $1.79 million; its owner also pleaded guilty. Defunct. Record · source: justice.gov.
• •Rats Army — FDA/DOJ criminal case. The operator was convicted for manufacturing and selling unapproved drugs under the Rat's Army name. Permanently closed; any storefront using the name today should be treated as unrelated. Record · source: fda.gov.
• •Proven Peptides — reported to have ceased operations around 2020 (third-party reference only; no government record). Record.
• •Prime Peptides — FDA warning letter, 10 December 2024 (MARCS-CMS 695156): semaglutide and retatrutide sold as unapproved new drugs, with social media directing consumers to purchase. One of four letters issued the same day. Storefront still live when last checked. Record · source: fda.gov.
• •Summit Research Peptides — FDA warning letter, 10 December 2024 (MARCS-CMS 695607): semaglutide, retatrutide, cagrilintide, tirzepatide and mazdutide; the research-use-only claim was deemed pretextual given human-use marketing. Still trading when last checked. Record · source: fda.gov.
• •Swiss Chems — FDA warning letter, 10 December 2024 (MARCS-CMS 695663): semaglutide and retatrutide as unapproved new drugs. Part of the same four-letter wave. Still trading when last checked. Record · source: fda.gov.
• •Amino Asylum — reported closed after an FDA warehouse raid in June 2025: site offline, no fulfilment; the domain now redirects to a parked page. The owner pleaded guilty on 10 December 2025. Record · industry record.
• •Paradigm Peptides — reported ceased operations; the founders pleaded guilty on 10 December 2025 (DOJ, N.D. Indiana). The site showed a closure notice and then returned an empty page. Record · industry record.
• •Pinnacle Peptides — FDA warning letter, 12 December 2025 (MARCS-CMS 719337): SARMs (S4 Andarine, LGD-4033, MK-2866) marketed as unapproved new drugs. Still trading as of the letter. Record · source: fda.gov.
• •Science.bio — announced a voluntary permanent closure on 27 January 2026 and discontinued research-product sales. Not raided or charged; the company said it would fulfil outstanding orders or refund them. Record · industry record.
• •Peptide Sciences — reported voluntary shutdown on 6 March 2026. The industry record describes it as the largest US grey-market vendor at the time, with no refund process and pending orders lost. Record · industry record.
• •Mile High Compounds — FDA warning letter, 31 March 2026 (MARCS-CMS 721600): products marketed as GLP-1, GLP-2 and GLP-3 analogues (semaglutide, tirzepatide, retatrutide) deemed unapproved new drugs; part of the spring-2026 GLP-1 enforcement wave. Still trading when last checked. Record · source: fda.gov.
• •Wholesale Peptides — FDA warning letter, 17 June 2026 (MARCS-CMS 729447): unapproved new drugs. When re-checked in July the storefront was live with the two cited products removed and the catalogue moved behind a login gate. Record · source: fda.gov.

Each entry's check date is printed on the watch page. The whole table is downloadable as CSV or JSON under CC BY 4.0.

What a warning letter is, and is not

An FDA warning letter is a leading indicator, not a closure. It states which products the agency considers unapproved new drugs and gives the firm time to respond. Of the eight letters above, six firms were still trading when PepAssure last checked. A letter also says nothing about purity: a vendor's independent lab results stay on its page beside the regulatory record, because the two describe different things — what was in a tested vial, and what the agency says about the business. We show both so you can weigh them.

A reported shutdown is weaker evidence than a government record and is labelled as such. Where the only source is a third-party review site, the entry says so and the watch page de-emphasises it.

If you bought from one of these vendors

• •Open order with a closed vendor: keep the confirmation and contact your payment provider. Orders placed after a closure are unlikely to be fulfilled.
• •Product on hand: the lab results and certificates on the vendor's PepAssure page stay published after a closure, so you can still check what a batch tested at. Verify any certificate you hold against the lab's own lookup — our testing labs page lists which labs offer one.
• •A new site with the same name: treat it as a different business unless the record says otherwise. Compare the domain with the one on the vendor's page before ordering.

Corrections

Every entry links to its source and carries the date it was last checked. If a record is wrong or has been superseded — a letter closed out, a closure reversed — use corrections; we acknowledge within 72 hours and note material changes on the page.